Il pretrattamento con ticlopidina nello stent coronarico è associato a significativa riduzione di eventi avversi. Dati dal trial EPISTENT.

Translated title of the contribution: Ticlopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial

Research output: Contribution to journalArticlepeer-review

Translated title of the contributionTiclopidine pretreatment before coronary stenting is associated with sustained decrease in adverse events. Data from the Evaluation of Platelets IIb/IIIa Inhibitor for Stenting (EPISTENT) Trial
Original languageItalian
Pages (from-to)805-806
Number of pages2
JournalItalian Heart Journal
Volume2
Issue number7 Suppl
Publication statusPublished - Jul 2001

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this